Search Results - "Scheltens, Philip"

Heterogeneity of Alzheimer's disease: consequence for drug trials? by Devi, Gayatri, Scheltens, Philip

“…Alzheimer's disease is a heterogenous disorder with multiple phenotypes and genotypes, although they eventually converge to a final common clinicopathological…”
Get full text

The "rights" of precision drug development for Alzheimer's disease by Cummings, Jeffrey, Feldman, Howard H, Scheltens, Philip

“…There is a high rate of failure in Alzheimer's disease (AD) drug development with 99% of trials showing no drug-placebo difference. This low rate of success…”
Get full text

Timely Diagnosis for Alzheimer's Disease: A Literature Review on Benefits and Challenges by Dubois, Bruno, Padovani, Alessandro, Scheltens, Philip, Rossi, Andrea, Dell'Agnello, Grazia

“…Timely diagnosis of Alzheimer's disease (AD) refers to a diagnosis at the stage when patients come to the attention of clinicians because of concerns about…”
Get more information

Early restoration of parvalbumin interneuron activity prevents memory loss and network hyperexcitability in a mouse model of Alzheimer’s disease by Hijazi, Sara, Heistek, Tim S., Scheltens, Philip, Neumann, Ulf, Shimshek, Derya R., Mansvelder, Huibert D., Smit, August B., van Kesteren, Ronald E.

“…Neuronal network dysfunction is increasingly recognized as an early symptom in Alzheimer’s disease (AD) and may provide new entry points for diagnosis and…”
Get full text

The probabilistic model of Alzheimer disease: the amyloid hypothesis revised by Frisoni, Giovanni B., Altomare, Daniele, Thal, Dietmar Rudolf, Ribaldi, Federica, van der Kant, Rik, Ossenkoppele, Rik, Blennow, Kaj, Cummings, Jeffrey, van Duijn, Cornelia, Nilsson, Peter M., Dietrich, Pierre-Yves, Scheltens, Philip, Dubois, Bruno

“…The current conceptualization of Alzheimer disease (AD) is driven by the amyloid hypothesis, in which a deterministic chain of events leads from amyloid…”
Get full text

Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes by Verberk, Inge M. W., Slot, Rosalinde E., Verfaillie, Sander C. J., Heijst, Hans, Prins, Niels D., van Berckel, Bart N. M., Scheltens, Philip, Teunissen, Charlotte E., van der Flier, Wiesje M.

“…Objective We investigated the association of plasma amyloid beta (Abeta)40, Abeta42, and total tau (tTau) with the presence of Alzheimer pathological changes…”
Get full text

Current state of Alzheimer’s fluid biomarkers by Molinuevo, José Luis, Ayton, Scott, Batrla, Richard, Bednar, Martin M., Bittner, Tobias, Cummings, Jeffrey, Fagan, Anne M., Hampel, Harald, Mielke, Michelle M., Mikulskis, Alvydas, O’Bryant, Sid, Scheltens, Philip, Sevigny, Jeffrey, Shaw, Leslie M., Soares, Holly D., Tong, Gary, Trojanowski, John Q., Zetterberg, Henrik, Blennow, Kaj

“…Alzheimer’s disease (AD) is a progressive neurodegenerative disease with a complex and heterogeneous pathophysiology. The number of people living with AD is…”
Get full text

A clinical-radiological framework of the right temporal variant of frontotemporal dementia by Ulugut Erkoyun, Hulya, Groot, Colin, Heilbron, Ronja, Nelissen, Anne, van Rossum, Jonathan, Jutten, Roos, Koene, Ted, van der Flier, Wiesje M, Wattjes, Mike P, Scheltens, Philip, Ossenkoppele, Rik, Barkhof, Frederik, Pijnenburg, Yolande

“…The concept of the right temporal variant of frontotemporal dementia (rtvFTD) is still equivocal. The syndrome accompanying predominant right anterior temporal…”
Get full text

A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease by Ostrowitzki, Susanne, Lasser, Robert A, Dorflinger, Ernest, Scheltens, Philip, Barkhof, Frederik, Nikolcheva, Tania, Ashford, Elizabeth, Retout, Sylvie, Hofmann, Carsten, Delmar, Paul, Klein, Gregory, Andjelkovic, Mirjana, Dubois, Bruno, Boada, Mercè, Blennow, Kaj, Santarelli, Luca, Fontoura, Paulo

“…Gantenerumab is a fully human monoclonal antibody that binds aggregated amyloid-β (Aβ) and removes Aβ plaques by Fc receptor-mediated phagocytosis. In the…”
Get full text

Alzheimer's disease: connecting findings from graph theoretical studies of brain networks by Tijms, Betty M, Wink, Alle Meije, de Haan, Willem, van der Flier, Wiesje M, Stam, Cornelis J, Scheltens, Philip, Barkhof, Frederik

“…Abstract The interrelationships between pathological processes and emerging clinical phenotypes in Alzheimer's disease (AD) are important yet complicated to…”
Get full text

MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases by Harper, Lorna, Fumagalli, Giorgio G, Barkhof, Frederik, Scheltens, Philip, O'Brien, John T, Bouwman, Femke, Burton, Emma J, Rohrer, Jonathan D, Fox, Nick C, Ridgway, Gerard R, Schott, Jonathan M

“…Accurately distinguishing between different degenerative dementias during life is challenging but increasingly important with the prospect of disease-modifying…”
Get full text

A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease by Jessen, Frank, Amariglio, Rebecca E, van Boxtel, Martin, Breteler, Monique, Ceccaldi, Mathieu, Chételat, Gaël, Dubois, Bruno, Dufouil, Carole, Ellis, Kathryn A, van der Flier, Wiesje M, Glodzik, Lidia, van Harten, Argonde C, de Leon, Mony J, McHugh, Pauline, Mielke, Michelle M, Molinuevo, Jose Luis, Mosconi, Lisa, Osorio, Ricardo S, Perrotin, Audrey, Petersen, Ronald C, Rabin, Laura A, Rami, Lorena, Reisberg, Barry, Rentz, Dorene M, Sachdev, Perminder S, de la Sayette, Vincent, Saykin, Andrew J, Scheltens, Philip, Shulman, Melanie B, Slavin, Melissa J, Sperling, Reisa A, Stewart, Robert, Uspenskaya, Olga, Vellas, Bruno, Visser, Pieter Jelle, Wagner, Michael

“…Abstract There is increasing evidence that subjective cognitive decline (SCD) in individuals with unimpaired performance on cognitive tests may represent the…”
Get full text

The clinical use of structural MRI in Alzheimer disease by Frisoni, Giovanni B, Fox, Nick C, Jack, Clifford R, Scheltens, Philip, Thompson, Paul M

“…MRI-based structural imaging has become an integral component of the clinical assessment of patients with suspected Alzheimer disease (AD), and atrophy of…”
Get full text

Brain Health: The Importance of Recognizing Cognitive Impairment: An IAGG Consensus Conference by Morley, John E., MB, BCh, Morris, John C., MD, Berg-Weger, Marla, PhD, LCSW, Borson, Soo, MD, Carpenter, Brian D., PhD, del Campo, Natalia, PhD, Dubois, Bruno, MD, Fargo, Keith, PhD, Fitten, L. Jaime, MD, Flaherty, Joseph H., MD, Ganguli, Mary, MD, MPH, Grossberg, George T., MD, Malmstrom, Theodore K., PhD, Petersen, Ronald D., PhD, MD, Rodriguez, Carroll, BSW, Saykin, Andrew J., PsyD, Scheltens, Philip, MD, Tangalos, Eric G., MD, Verghese, Joe, MBBS, Wilcock, Gordon, MD, Winblad, Bengt, MD, Woo, Jean, MD, Vellas, Bruno, MD

“…Abstract Cognitive impairment creates significant challenges for patients, their families and friends, and clinicians who provide their health care. Early…”
Get full text

Drug development in Alzheimer's disease: the path to 2025 by Cummings, Jeffrey, Aisen, Paul S, DuBois, Bruno, Frölich, Lutz, Jack, Jr, Clifford R, Jones, Roy W, Morris, John C, Raskin, Joel, Dowsett, Sherie A, Scheltens, Philip

“…The global impact of Alzheimer's disease (AD) continues to increase, and focused efforts are needed to address this immense public health challenge. National…”
Get full text

Global Burden of Small Vessel Disease–Related Brain Changes on MRI Predicts Cognitive and Functional Decline by Jokinen, Hanna, Koikkalainen, Juha, Laakso, Hanna M., Melkas, Susanna, Nieminen, Tuomas, Brander, Antti, Korvenoja, Antti, Rueckert, Daniel, Barkhof, Frederik, Scheltens, Philip, Schmidt, Reinhold, Fazekas, Franz, Madureira, Sofia, Verdelho, Ana, Wallin, Anders, Wahlund, Lars-Olof, Waldemar, Gunhild, Chabriat, Hugues, Hennerici, Michael, O’Brien, John, Inzitari, Domenico, Lötjönen, Jyrki, Pantoni, Leonardo, Erkinjuntti, Timo

“…BACKGROUND AND PURPOSE—Cerebral small vessel disease is characterized by a wide range of focal and global brain changes. We used a magnetic resonance imaging…”
Get full text

On the path to 2025: understanding the Alzheimer's disease continuum by Aisen, Paul S, Cummings, Jeffrey, Jack, Jr, Clifford R, Morris, John C, Sperling, Reisa, Frölich, Lutz, Jones, Roy W, Dowsett, Sherie A, Matthews, Brandy R, Raskin, Joel, Scheltens, Philip, Dubois, Bruno

“…Basic research advances in recent years have furthered our understanding of the natural history of Alzheimer's disease (AD). It is now recognized that…”
Get full text

Different patterns of gray matter atrophy in early- and late-onset Alzheimer’s disease by Möller, Christiane, Vrenken, Hugo, Jiskoot, Lize, Versteeg, Adriaan, Barkhof, Frederik, Scheltens, Philip, van der Flier, Wiesje M

“…Abstract We assessed patterns of gray matter atrophy according to-age-at-onset in a large sample of 215 Alzheimer’s disease (AD) patients and 129 control…”
Get full text

Activity dependent degeneration explains hub vulnerability in Alzheimer's disease by de Haan, Willem, Mott, Katherine, van Straaten, Elisabeth C W, Scheltens, Philip, Stam, Cornelis J

“…Brain connectivity studies have revealed that highly connected 'hub' regions are particularly vulnerable to Alzheimer pathology: they show marked amyloid-β…”
Get full text

Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ε4 allele by van der Flier, Wiesje M, PhD, Pijnenburg, Yolande AL, MD, Fox, Nick C, Prof, Scheltens, Philip, Prof

“…Summary Some patients with early-onset Alzheimer's disease (AD) present with a distinct phenotype. Typically, the first and most salient characteristic of AD…”
Get full text